US Patent 4,436,741: Scopolamine Transdermal Administration Claims and Patent Landscape

US Patent 4,436,741 covers a method of administering scopolamine base through unbroken skin after an initial skin-saturating dose, followed by substantially continuous delivery. The patent is a method-of-use patent, not a general product-composition patent. Its central limitations are a transdermal route, an initial dose sufficient to saturate skin binding sites, and a maintenance delivery rate generally ranging from 0.3 to 15 micrograms per hour.

The patent issued March 13, 1984, to Alza Corporation. Based on its pre-Uruguay Round filing date, the patent term generally ran for 17 years from issuance and expired in March 2001, absent an unusual term adjustment or enforceable extension. It is therefore not a current US blocking patent.

What does US Patent 4,436,741 protect?

The patent protects a pharmacokinetic method for achieving prolonged scopolamine administration through skin. It does not broadly claim every scopolamine patch or every transdermal delivery system.

Element	Scope under the claims
Active ingredient	Scopolamine base
Route	Transdermal administration
Skin condition	Predetermined area of unbroken skin
Initial phase	Skin-saturating dose or sufficient dose to occupy scopolamine binding sites
Initial dose in claim 1	About 10 to about 200 micrograms per square centimeter
Maintenance rate	About 0.3 to about 15 micrograms per hour
Pharmacokinetic result in claim 1	Urinary scopolamine excretion of about 0.05 to about 1.5 micrograms per hour
Duration	A prolonged period of time
Preferred site	Mastoidal area, under claim 3
Patient populations	Vestibular-disorder patients, pregnant patients, chemotherapy patients, radiation-therapy patients, and anesthetized patients

The invention's technical distinction is the use of an initial loading or saturation phase before maintaining a lower, substantially constant delivery rate. The claims focus on delivery behavior in the patient rather than solely on the physical construction of a patch.

How broad is independent claim 1?

Claim 1 requires all of the following:

Scopolamine is administered transdermally.
The administration occurs over a prolonged period.
Scopolamine base is applied to unbroken skin.
The initial amount is about 10 to 200 micrograms per square centimeter.
The subsequent delivery rate is about 0.3 to 15 micrograms per hour.
The rate is sufficient to maintain urinary scopolamine excretion at about 0.05 to 1.5 micrograms per hour.

The claim is narrower than a claim covering any scopolamine patch. A product or method that uses a different active ingredient, a non-transdermal route, a delivery rate outside the stated range, or no measurable urinary-excretion result would not literally satisfy every limitation.

The phrase "about" gives numerical ranges some practical flexibility. Its effect would depend on claim construction, specification disclosure, prosecution history, and technical evidence. It does not eliminate the need to prove that the accused method falls within the claimed dosage and rate parameters.

The urinary-excretion limitation also creates an evidentiary issue. An infringement case would likely require pharmacokinetic testing, product-performance data, clinical records, or expert modeling to establish whether the method maintained the specified urinary excretion range.

What is the scope of independent claim 2?

Claim 2 uses a different formulation of the same core concept. It requires:

administration of scopolamine base to unbroken skin;
administration until sufficient scopolamine has occupied the binding sites associated with that skin area; and
continuous administration at a substantially constant rate of 0.3 to 15 micrograms per hour.

Unlike claim 1, claim 2 does not expressly recite the 10 to 200 microgram-per-square-centimeter loading range or the urinary-excretion range. It instead uses the functional concept of skin-site saturation.

That distinction may make claim 2 broader in some respects, but it also creates a proof issue. A party asserting the claim would need to establish that the skin binding sites were occupied before or during the maintenance phase. The phrase "sufficient scopolamine" is functional and would likely be interpreted in light of the specification and the patent's experimental disclosure.

Claim 2 also requires continuous administration at a substantially constant rate. Intermittent dosing, ordinary oral dosing, or a delivery system with substantial rate fluctuation would present noninfringement arguments.

What do claims 3 through 11 add?

The dependent claims narrow the independent method claims by adding administration sites, patient groups, or rate ranges.

Claim	Added limitation	Practical significance
3	Application to the mastoidal area	Covers the area behind or near the ear, consistent with the commercial scopolamine patch site
4	Patient has a vestibular disturbance	Targets motion sickness and related vestibular indications
5	Maintenance rate of 5 to 15 micrograms per hour for adults and 3 to 10 micrograms per hour for children	Adds patient-specific rate ranges
6	Claim 3 plus the adult and pediatric rate ranges	Narrows claim 5 to mastoidal administration
7	Claim 5 plus a saturation dose of 10 to 200 micrograms per square centimeter	Reintroduces the loading-dose limitation
8	Patient is pregnant	Covers a patient subgroup rather than a distinct formulation
9	Patient is undergoing chemotherapy	Addresses chemotherapy-associated nausea and vomiting
10	Patient is undergoing radiation therapy	Addresses radiation-associated nausea and vomiting
11	Patient is treated with an anesthetic	Addresses perioperative nausea and vomiting

Claims 8 through 11 are method-of-use claims. They do not claim a new formulation specifically adapted for those populations. They would require proof that the accused product was administered to a patient in the specified circumstance.

What patent protects the commercial Transderm Scop product?

US Patent 4,436,741 is one part of the historical intellectual-property framework surrounding transdermal scopolamine. It should not be treated as the only patent relevant to the commercial product.

Transdermal scopolamine products historically relied on several potential patent categories:

Delivery-system patents. These cover reservoir systems, membranes, adhesives, backing layers, drug reservoirs, and release-control structures.
Method-of-use patents. These cover administration for motion sickness, vestibular disorders, postoperative nausea, chemotherapy-related nausea, or other conditions.
Dosing patents. These cover loading doses, maintenance rates, delivery duration, and pharmacokinetic targets.
Manufacturing patents. These may cover fabrication of the patch, drug incorporation, adhesive processing, or quality-control methods.
Regulatory exclusivity. FDA exclusivity may restrict approval of a competing application independently of patent rights.

The patent at issue is principally in the second and third categories. It does not, based on the supplied claims, require a particular patch architecture, adhesive chemistry, membrane, backing material, or manufacturing process.

When did US Patent 4,436,741 expire?

The patent issued on March 13, 1984. For a US patent governed by the pre-1995 patent-term regime, the ordinary term was 17 years from issuance. On that basis, the expected expiration date was March 13, 2001. The patent is therefore expired and cannot presently support an injunction against a US generic or competing transdermal scopolamine product.

Event	Date
Priority date	May 7, 1981
US filing date	May 6, 1982
Patent issue date	March 13, 1984
Expected ordinary expiration	March 13, 2001
Current enforceability	Expired

The expiration of this patent does not establish that every other patent associated with a scopolamine transdermal product has expired. A later-issued formulation, device, manufacturing, or method-of-use patent would require separate analysis.

What is the Orange Book status of US Patent 4,436,741?

US Patent 4,436,741 is not a current enforceable Orange Book barrier because it has expired. Historical Orange Book listings, if any, would not restore patent enforceability after expiration.

For an approved transdermal scopolamine product, Orange Book analysis should separate:

listed patents that have expired;
unexpired formulation or device patents;
unexpired method-of-use patents;
regulatory exclusivity;
patents listed against the reference listed drug;
patents relevant only to a particular indication or dosage form.

FDA patent listing does not itself determine ultimate validity or infringement. The listing identifies patents submitted by the NDA holder under FDA's patent-listing framework. Patent scope remains a matter for claim construction and infringement analysis. The FDA Orange Book identifies approved products, therapeutic equivalence information, patent listings, and exclusivity data, but it does not adjudicate patent validity.[2]

Are Paragraph IV challenges relevant to this patent?

A Paragraph IV challenge to US Patent 4,436,741 would no longer be commercially significant because the patent has expired. A generic applicant could historically have addressed the patent through a Paragraph IV certification if it remained listed and unexpired, but an expired patent does not provide the same litigation or 30-month-stay leverage.

For a current generic scopolamine transdermal product, the relevant certification analysis would focus on any unexpired patents listed for the reference product. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. A section viii statement may be used where the applicant seeks approval only for indications not covered by a listed method-of-use patent.

US Patent 4,436,741 is therefore primarily relevant as prior art, prosecution history, historical technology, and evidence of the original claimed dosing concept. It is not a current Paragraph IV launch blocker.

Which companies are challenging or competing with the patent?

No active US challenge to this expired patent is required for generic entry. Competition instead depends on FDA approval of an alternative transdermal scopolamine product and on any surviving patents covering the current reference product.

The competitive field has included:

the branded Transderm Scop product;
generic scopolamine transdermal systems approved through the ANDA pathway;
potential alternative transdermal delivery systems;
non-transdermal antiemetic products, including oral, injectable, and other dosage forms.

Because the claims are directed to administration of scopolamine rather than a named commercial patch, an approved generic using substantially the same dosing method could have historically faced method-of-use and product-patent issues. After expiration, the claims no longer create a US patent-based launch barrier.

How strong is the patent estate for this technology?

The expired patent's historical estate was commercially important but currently weak as an exclusionary asset. Its strengths were:

coverage of the core loading-dose and maintenance-rate concept;
claims directed to practical clinical administration;
dependent claims covering the mastoidal site;
coverage of several antiemetic and vestibular patient groups;
functional claims tied to sustained systemic exposure.

Its weaknesses were:

expiration in 2001;
dependence on pharmacokinetic and dosing facts;
potential ambiguity in "substantially constant," "prolonged," and "saturating" language;
limited coverage of patch structure and manufacturing;
patient-specific claims requiring proof of the treatment context;
possible design-around options using different rates, loading strategies, delivery sites, or formulations.

For current diligence, the material question is not whether 4,436,741 is valid. It is whether later patents cover the physical patch, adhesive, release profile, manufacturing process, or an approved indication.

What generic launch risks exist?

The patent-specific risk from US 4,436,741 is zero as an enforceable exclusion right because the patent has expired. Current launch risks are regulatory and commercial rather than dependent on this patent.

Risk category	Relevance to 4,436,741
Patent injunction	None from this expired patent
Paragraph IV litigation	Historical only
30-month stay	Not created by this expired patent
Formulation patent risk	Must be reviewed separately
Device patent risk	Must be reviewed separately
Method-of-use patent risk	Depends on later listed patents
FDA approval risk	Independent of patent expiration
Manufacturing know-how	May remain confidential even without patent protection
Market-entry risk	Depends on approved competitors, supply, and commercial scale

A generic manufacturer also may design around the claimed method by using a different delivery rate, a different initial dosing strategy, or a formulation that does not produce the claimed pharmacokinetic result. Such design-around analysis must account for potential equivalents arguments, although expired patent rights eliminate the present enforcement issue for this patent.

How does US 4,436,741 compare with formulation and device patents?

Issue	US 4,436,741	Formulation or device patent
Claim type	Method of administration	Product, system, composition, or manufacturing method
Core limitation	Loading and maintenance delivery of scopolamine	Patch architecture, adhesive, membrane, reservoir, or formulation
Proof required	Patient treatment and delivery behavior	Product testing and structural or compositional analysis
Patient-specific limitations	Yes	Usually no
Urinary-excretion limitation	Claim 1 includes it	Usually absent
Design-around path	Change dosing or administration method	Change materials, structure, or manufacturing process
Current status	Expired	Must be checked individually

Key Takeaways

US Patent 4,436,741 covers prolonged transdermal administration of scopolamine base after skin saturation.
Claim 1 requires an initial dose of about 10 to 200 micrograms per square centimeter, a maintenance rate of about 0.3 to 15 micrograms per hour, and a specified urinary-excretion result.
Claim 2 uses skin-binding-site saturation instead of the express loading-dose and urinary-excretion limitations.
Claims 3 through 11 narrow the methods by site, dose rate, age group, vestibular disease, pregnancy, chemotherapy, radiation therapy, and anesthetic treatment.
The patent issued March 13, 1984, and ordinarily expired March 13, 2001.
It is not a current US patent barrier to generic transdermal scopolamine entry.
Current diligence should focus on later formulation, device, manufacturing, and method-of-use patents, plus FDA Orange Book listings and regulatory exclusivity for the relevant reference product.
No biosimilar pathway applies. Scopolamine is a small-molecule drug, so competing products generally proceed through the ANDA or NDA pathways rather than the biosimilar pathway.

FAQs

Does US Patent 4,436,741 cover the scopolamine patch itself?

No. The supplied claims cover methods of administering scopolamine. They do not expressly claim a particular patch structure, adhesive, membrane, backing, or reservoir.

Could a generic manufacturer launch after the expiration of US 4,436,741?

Yes, this patent no longer provides an enforceable US exclusion right. The manufacturer must still satisfy FDA approval requirements and assess any later unexpired patents.

Does claim 1 require proof of urinary scopolamine levels?

Yes. Literal infringement of claim 1 would require proof that the delivery rate was sufficient to maintain urinary scopolamine excretion within the claimed range.

Does the mastoidal-area limitation apply to every claim?

No. It appears in claims 3 and 6 through their dependency structure. Claims 1, 2, 4, 5, and 7 through 11 do not all require mastoidal administration.

Can a later patent extend the protection originally provided by US 4,436,741?

No. A later patent may protect a different invention, such as a formulation, device, or manufacturing process, but it cannot extend the expired term of US 4,436,741.

References

United States Patent and Trademark Office. (1984). Method for administering scopolamine transdermally (U.S. Patent No. 4,436,741).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
U.S. Food and Drug Administration. (2024). Approved drug product label: Transderm Scop (scopolamine transdermal system).
United States Code, 35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights.

Details for Patent: 4,436,741

Summary for Patent: 4,436,741